The first 10 drugs identified for negotiations under the Inflation Reduction Act include several well advertised agents indicated to treat diabetes, heart failure, and other chronic diseases.
The newly named centers across the country will work closely with communities to focus research on populations at greatest risk for perinatal morbidity and mortality.
Patients with diabetes will be able to save money when ordering insulin and commonly prescribed products, such as continuous glucose monitors and pumps.
Excess CVD mortality among Black vs White adults was diminished after control for behavior/metabolic factors and negligible after adjustments for SDOH, a new study reveals.